Evidence map›Paper›PMID 27207921›Full record

ArticleThe international journal of neuropsychopharmacology2016

Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3.

Yan Leng, Junyu Wang, Zhifei Wang, Hsiao-Mei Liao, Monica Wei, Peter Leeds, De-Maw Chuang

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yan LengMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD. chuang@mail.nih.gov lengy@mail.nih.gov.
Junyu WangMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Zhifei WangMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Hsiao-Mei LiaoMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Monica WeiMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Peter LeedsMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
De-Maw ChuangMolecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD. chuang@mail.nih.gov lengy@mail.nih.gov.
National Institute of Mental Health · USNational Institutes of Health · US

Funding

Mechanisms Of Action Of Psychoactive DrugsZIAMH002468 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI AMARA, SUSAN · 2009 to 2015
$10.1M
Intramural NIH HHS ZIA MH002468
6 · The paper itself

Abstract

backgroundFibroblast growth factor 21, a novel regulator of glucose and lipid metabolism, has robust protective properties in neurons. However, its expression and function in glia are unknown. Valproic acid, a mood stabilizer and anticonvulsant, is a histone deacetylase inhibitor and a dynamic gene regulator. We investigated whether histone deacetylase inhibition by valproic acid and other inhibitors upregulates fibroblast growth factor 21 expression and, if so, sought to identify the histone deacetylase isoform(s) involved and their role in altering glial cell morphology.

methodsC6 glioma or primary cortical glial cultures were treated with histone deacetylase inhibitors, and fibroblast growth factor 21 levels and length of cell processes were subsequently measured. Histone deacetylase 1, 2, or 3 was also knocked down to detect which isoform was involved in regulating fibroblast growth factor 21 mRNA levels. Finally, knockdown and overexpression of fibroblast growth factor 21 were performed to determine whether it played a role in regulating cell process length.

resultsTreatment of C6 cells or primary glial cultures with valproic acid elevated fibroblast growth factor 21 mRNA levels, extended cell process length, and markedly increased acetylated histone-H3 levels. Other histone deacetylase inhibitors including pan- and class I-specific inhibitors, or selective knockdown of histone deacetylase 2 or 3 isoform produced similar effects. Knockdown or overexpression of fibroblast growth factor 21 significantly decreased or increased C6 cell process length, respectively.

conclusionsIn glial cell line and primary glia, using pharmacological inhibition and selective gene silencing of histone deacetylases to boost fibroblast growth factor 21 mRNA levels results in elongation of cell processes. Our study provides a new mechanism via which histone deacetylase 2 and 3 participate in upregulating fibroblast growth factor 21 transcription and extending process outgrowth in glia.

Indexed as

AcetylationCell ShapeFibroblast Growth FactorsGene Knockdown TechniquesHistone Deacetylase 2Histone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesHumansIsoenzymesNeurogliaPrimary Cell CultureUp-RegulationValproic Acidfibroblast growth factor 21Fibroblast Growth FactorsHistone Deacetylase 2Histone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesIsoenzymesValproic Acidcell processesFGF21glial cellsHDAC inhibitorsvalproic acid

Identifiers

PMID27207921
PMCPMC5006201
OpenAlexW2340552375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.